1. CytoSorb® therapy: a new approach to treat critically ill patients with COVID-19 – a retrospective study
- Author
-
K. Patil and M. Priyadarsini
- Subjects
cytokines ,covid-19 ,sepsis ,hemoadsorption ,acute respiratory distress syndrome ,coronavirus ,cytosorb® ,Computer applications to medicine. Medical informatics ,R858-859.7 - Abstract
Objective: The Coronavirus 2019 (COVID-19) pandemic has resulted in significant mortality and morbidity. Patients with severe COVID-19 infection experience cytokine storm that makes the treatment approach more challenging. The aim of the present study was to evaluate the effects of CytoSorb® therapy in COVID-19 patients admitted in ICU. Patients and Methods: This was a single-center, retrospective study conducted at Sunshine Hospital, Hyderabad, India from January 2020 to November 2020. Patients diagnosed with COVID-19 along with signs of sepsis and with a minimum of one organ dysfunction were enrolled in the study. All the patients were treated with CytoSorb® therapy. Clinical and laboratory parameters such as procalcitonin (PCT), serum lactate, interleukin-6 (IL-6), mean arterial pressure (MAP), C-Reactive Protein and the patients’ length of stay in intensive care were measured. Results: A total of 20 patients were enrolled in this study; of these 13 patients (65%) survived. One patient left against medical advice and was thus excluded from the analysis. Post CytoSorb® therapy, a reduction in the levels of PCT, total leucocyte count (TLC), and platelet count in the survivor group was reported. The dosage of norepinephrine decreased by 46% in the survivor group but decreased by 0.8% in the non-survivor group (p= 0.0424 for survivor vs. non survivors). The average number of days spent by all patients in ICU was 9±5.25. Conclusions: The use of CytoSorb® therapy for patients with COVID-19 is a safe and effective treatment option when initiated in a timely manner.
- Published
- 2023
- Full Text
- View/download PDF